Treatment with oral sucrosomial iron + Treatment with intravenous iron
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Anemia
Conditions
Anemia, Iron Deficiency Anemia
Trial Timeline
Dec 31, 2025 → Jun 30, 2027
NCT ID
NCT07287371About Treatment with oral sucrosomial iron + Treatment with intravenous iron
Treatment with oral sucrosomial iron + Treatment with intravenous iron is a approved stage product being developed by Pharmanutra for Anemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07287371. Target conditions include Anemia, Iron Deficiency Anemia.
What happened to similar drugs?
20 of 20 similar drugs in Anemia were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
20
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07287371 | Approved | Recruiting |
Competing Products
20 competing products in Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aranesp® | Amgen | Approved | 43 |
| KER-047 | Keros Therapeutics | Phase 2 | 17 |
| LY2787106 | Eli Lilly | Phase 1 | 29 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 40 |
| epoetin beta + placebo | Chugai Pharmaceutical | Phase 3 | 40 |
| recombinant human erythropoietin + recombinant human erythropoietin placebo | Chugai Pharmaceutical | Phase 3 | 40 |
| recombinant human erythropoietin + recombinant human erythropoietin | Chugai Pharmaceutical | Phase 3 | 40 |
| darbepoetin alfa | Amgen | Phase 3 | 40 |
| Prasugrel | Daiichi Sankyo | Phase 1 | 29 |
| Prasugrel + Placebo | Daiichi Sankyo | Phase 2 | 35 |
| roxadustat | Astellas Pharma | Phase 3 | 40 |
| roxadustat | Astellas Pharma | Phase 3 | 40 |
| Roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 40 |
| Alefacept | Astellas Pharma | Phase 1 | 21 |
| Roxadustat | Astellas Pharma | Phase 2 | 35 |
| roxadustat | Astellas Pharma | Phase 1 | 29 |
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 40 |
| Roxadustat | Astellas Pharma | Pre-clinical | 26 |
| Roxadustat + Epoetin Alfa | Astellas Pharma | Phase 3 | 40 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 40 |